General partners
Medtronic

As a global leader in medical technology, services and solutions, Medtronic improves the health and lives of millions of people each year. We believe our deep clinical, therapeutic and economic expertise can help address the complex challenges — such as rising costs, aging populations and the burden of chronic disease — faced by families and healthcare systems today. But no one can do it alone. That’s why we’re committed to partnering in new ways and developing powerful solutions that deliver better patient outcomes. Founded in 1949 as a medical repair company, we’re now among the world’s largest medical technology, services and solutions companies, employing more than 85,000 people worldwide, serving physicians, hospitals and patients in nearly 155+ countries.

Join us in our commitment to take healthcare Further, Together. Learn more at Medtronic.com.

Official partners
Ipsen

Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s vision is to become a leading global biotech company focused on innovation and specialty care. Ipsen’s commitment to oncology is exemplified through its growing portfolio. Ipsen sells 7 drugs in primary care and specialty including aesthetics.

MSD

For over 100 years, MSD (Merck Sharp & Dohme) is one of the leading global biopharmaceutical company. MSD is a trademark of Merck & Co., Inc., headquartered in Kenilworth, New Jersey, USA. MSD portfolio includes products for treatment and prevention of cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola and others.

For more information visit www.msd.ru or www.msd.com.

Sanofi

Sanofi group is one of the global healthcare leaders. All of the company’s activities – medicine development, production and market entry are focused on finding the best solutions for customer’s and patient’s needs.

The company's oncology portfolio is represented in such nosologies as breast and pancreatic cancer - Abraxane; prostate cancer - Jevtana; thyroid cancer - Thyrogen, Caprelsa; colorectal cancer - Zaltrap.

Takeda

Takeda Pharmaceuticals, LLC located in Moscow, is the Russian marketing and sales organization of Takeda Pharmaceutical Company Limited, Osaka, Japan. For more than 20 years company has been striving to bring better health and brighter future for patients in Russia and CIS with more than 1800 employees working in 135 cities all over the region. Takeda is among the Top10 companies on the Russian pharmaceutical market. In 2013 Takeda opened its new state-of-the-art production site in Yaroslavl.

Special partners
MERCK

Merck is a leading science and technology company in the healthcare, life science and performance materials sectors. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions.

Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand.

Partners
R-Pharm

R-Pharm is a Russian hi-tech pharmaceutical company that is involved in R&D, manufacturing and sales of medicines. R-Pharm operates in 9 countries throughout the world, it has over 60 branches and subsidiaries.

Roche Moscow Ltd.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.ru